Activated Protein C Resistan Test at Dr. Essa Lab Karachi

Activated Protein C Resistan at Dr. Essa Lab

The Activated Protein C Resistan test at Dr. Essa Lab is a highly specialized hematological and coagulation assay designed to evaluate a patient’s risk of developing abnormal blood clots. This diagnostic investigation is crucial for identifying inherited and acquired thrombophilic states, which predispose individuals to venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE). By measuring the clotting system’s response to activated protein C (APC), this test serves as a primary screening tool for the Factor V Leiden mutation, the most common genetic risk factor for thrombosis in Caucasian populations. Dr. Essa Laboratory & Diagnostic Centre, a pioneer in diagnostic services in Karachi, Pakistan, utilizes advanced automated coagulation analyzers to perform this assay with the highest degree of clinical precision and reproducibility.

The coagulation cascade is a complex physiological process involving a series of enzymatic reactions that ultimately lead to the formation of a stable fibrin clot. To prevent excessive clotting, the body employs natural anticoagulant pathways, one of the most critical being the protein C pathway. Under normal physiological conditions, thrombin binds to thrombomodulin on the endothelial surface, activating protein C. Activated protein C, along with its cofactor protein S, then cleaves and inactivates activated coagulation factors V (FVa) and VIII (FVIIIa), thereby downregulating the clotting process. When a patient exhibits Activated Protein C Resistan, this inhibitory mechanism is impaired. Consequently, factors FVa and FVIIIa remain active longer, promoting a hypercoagulable state that significantly elevates the risk of thrombotic events.

Understanding the clinical importance of the Activated Protein C Resistan assay is vital for patients presenting with unexplained thromboembolic events. The diagnostic value of this test lies in its ability to differentiate between normal coagulation profiles and those characterized by resistance to APC-mediated inactivation. The primary benefit of undergoing this test at Dr. Essa Lab is the early identification of thrombophilia, which allows clinicians to make informed decisions regarding long-term anticoagulation therapy, prophylactic measures during high-risk periods (such as surgery, pregnancy, or prolonged immobilization), and lifestyle modifications. Common indications for this test include a history of recurrent venous thrombosis, thrombosis at an unusual anatomical site (such as the cerebral, mesenteric, or hepatic veins), a strong family history of venous thromboembolism, and recurrent unexplained pregnancy losses.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is essential to ensure the accuracy and clinical validity of the Activated Protein C Resistan test. Because this is a functional clotting assay, various external factors, particularly medications, can significantly interfere with the results. Patients must strictly adhere to the following preparation guidelines:

• Anticoagulant Therapy Discontinuation: The patient must not be on active anticoagulant therapy when the sample is drawn. Heparin, warfarin, and direct oral anticoagulants (DOACs) such as rivaroxaban and apixaban can prolong clotting times and cause false-positive or uninterpretable results. Typically, the test should be performed at least two weeks after discontinuing oral anticoagulants and after heparin therapy has ceased, strictly under the supervising physician’s guidance.
• Timing Post-Thrombotic Event: The test should ideally not be performed during an acute thrombotic episode or immediately after. The consumption of coagulation factors during an acute event can skew the results. It is generally recommended to wait at least 3 to 6 months post-event.
• No Fasting Required: Standard dietary fasting is not mandatory for this blood test. However, patients are advised to avoid excessively fatty meals immediately before the blood draw, as lipemia can interfere with optical clot detection systems.
• Hydration: Adequate hydration is highly recommended to facilitate venipuncture and ensure a smooth blood draw.
• Medical History Disclosure: Patients must inform the laboratory staff of all current medications, history of liver disease, pregnancy status, or recent inflammatory conditions, as these can influence plasma levels of coagulation proteins.

During the Procedure

The Activated Protein C Resistan test is performed on a peripheral blood sample, and the collection process follows strict clinical protocols to preserve the integrity of the coagulation factors:

• Patient Positioning: The patient is comfortably seated or placed in a recumbent position. The phlebotomist identifies a suitable vein, typically in the antecubital fossa of the arm.
• Aseptic Technique: The skin over the selected vein is thoroughly cleansed with an antiseptic solution to prevent contamination.
• Venipuncture and Sample Collection: A tourniquet is applied briefly to locate the vein. A skilled phlebotomist performs the venipuncture using a sterile needle. The blood is collected directly into a light blue-top tube containing 3.2% sodium citrate as an anticoagulant. The ratio of blood to anticoagulant (9:1) is critical; hence, the tube must be filled precisely to the indicated mark.
• Inversion and Mixing: Immediately after collection, the tube is gently inverted 3 to 4 times to ensure thorough mixing of the blood with the sodium citrate, preventing micro-clot formation.
• Duration and Experience: The entire blood collection procedure takes less than five minutes. The patient may feel a brief, mild pinch as the needle enters the vein.
• Post-Procedure Care: Pressure is applied to the puncture site with a sterile cotton ball, followed by the application of a bandage to prevent bruising or hematoma formation.
• Safety Considerations: The procedure is extremely safe, with minimal risks such as minor bruising, localized soreness, or very rarely, a transient feeling of lightheadedness.

When is a Activated Protein C Resistan Performed?

Unexplained Venous Thromboembolism (VTE)

Physicians routinely request the Activated Protein C Resistan test when a patient presents with an unexplained venous thromboembolic event, particularly at a young age (under 50 years). Venous thromboembolism encompasses deep vein thrombosis and pulmonary embolism, which can be life-threatening if left untreated. When a clot occurs without an obvious provoking factor—such as major surgery, severe trauma, or active malignancy—an underlying genetic predisposition is highly suspected. Identifying resistance to activated protein C helps clinicians determine if the patient has an inherited thrombophilic condition, which directly influences the duration and intensity of secondary anticoagulant prophylaxis to prevent recurrence.

Recurrent Deep Vein Thrombosis (DVT)

Recurrent episodes of deep vein thrombosis, especially despite standard anticoagulation or shortly after stopping treatment, warrant a comprehensive thrombophilia workup, including the Activated Protein C Resistan assay. Patients with recurrent DVT often experience chronic complications such as post-thrombotic syndrome, characterized by chronic leg pain, swelling, and ulceration. By determining if the patient exhibits resistance to activated protein C, the medical team can assess the ongoing risk of clot recurrence. This diagnostic insight is crucial for deciding whether lifelong anticoagulation therapy is indicated to safeguard the patient’s vascular health.

Family History of Thrombophilia

A strong family history of premature venous thromboembolism or documented genetic thrombophilia (such as the Factor V Leiden mutation) is a major clinical indication for this test. Individuals who have first-degree relatives with a history of severe or recurrent blood clots may undergo screening to assess their personal risk profile. Knowing one’s thrombophilic status is highly beneficial, as it allows for targeted prophylactic interventions during transient high-risk situations, such as long-haul flights, major surgical procedures, or periods of prolonged bed rest, thereby preventing the first onset of a potentially devastating thrombotic event.

Unexplained Pregnancy Loss or Complications

The Activated Protein C Resistan test is frequently indicated for women who have experienced recurrent unexplained pregnancy losses (typically three or more early miscarriages or a single late-term fetal loss) or severe obstetric complications such as preeclampsia, placental abruption, or intrauterine growth restriction (IUGR). Placental blood vessels are highly susceptible to micro-thrombosis, which can impair uteroplacental circulation and lead to adverse pregnancy outcomes. Detecting an underlying resistance to activated protein C enables obstetricians and hematologists to collaborate on specialized treatment plans, which may include low-molecular-weight heparin (LMWH) therapy to improve gestational outcomes.

Evaluation Prior to Estrogen Therapy

Before prescribing estrogen-containing medications, such as combined oral contraceptive pills or hormone replacement therapy (HRT), physicians may recommend screening for Activated Protein C Resistan in women with a borderline personal or family history of clotting disorders. Estrogen naturally increases the levels of several procoagulant factors while decreasing natural anticoagulants, inducing a mild state of acquired APC resistance. In women who already have an underlying genetic resistance, the addition of exogenous estrogen exponentially increases the risk of venous thrombosis. Screening helps in selecting safer, progesterone-only or non-hormonal alternatives.

What Does a Activated Protein C Resistan Detect?

The Activated Protein C Resistan test is a highly sensitive functional assay that detects various abnormalities within the protein C anticoagulant pathway. Specifically, the test is capable of identifying and characterizing the following clinical findings and physiological states:

• Factor V Leiden Mutation: The test is primarily used to detect the presence of the Factor V Leiden mutation (G1691A), where a single nucleotide substitution alters the cleavage site on Factor V, making it resistant to inactivation by activated protein C.
• Heterozygous Factor V Leiden: It identifies individuals carrying one copy of the mutated gene, who have a 3- to 8-fold increased risk of developing venous thrombosis.
• Homozygous Factor V Leiden: It detects individuals carrying two copies of the mutated gene, presenting with a massive 50- to 80-fold increased risk of thrombotic events.
• Acquired Activated Protein C Resistance: The test can identify non-genetic, acquired resistance to APC, which can occur due to altered plasma concentrations of coagulation factors.
• Pregnancy-Induced APC Resistance: It detects the physiological increase in factor VIII and decrease in protein S during pregnancy, which naturally leads to a state of acquired resistance.
• Oral Contraceptive Use: It identifies the influence of third-generation oral contraceptives, which can significantly alter coagulation factor levels and induce APC resistance.
• Hormone Replacement Therapy (HRT) Effects: It detects changes in the coagulation profile caused by exogenous estrogen administration in postmenopausal women.
• Elevated Factor VIII Levels: High circulating levels of Factor VIII can compete with the inactivation process, leading to a functional resistance to APC.
• Lupus Anticoagulant Interference: The assay can detect the presence of antiphospholipid antibodies (lupus anticoagulants) which interfere with phospholipid-dependent clotting assays, causing a false-positive APC resistance result.
• Protein S Deficiency: Since protein S is a necessary cofactor for APC, a deficiency in protein S can manifest as a reduced response to APC in functional assays.
• Protein C Deficiency: While primarily evaluating resistance, severe abnormalities in the protein C pathway can be reflected in abnormal clotting ratio profiles.
• Active Thrombotic States: The test can reflect the hypercoagulable state present during or immediately following an acute thrombotic event.
• Liver Disease Impact: It detects alterations in clotting times caused by impaired hepatic synthesis of coagulation factors and natural anticoagulants.
• Neoplastic Hypercoagulability: It can identify acquired prothrombotic states associated with certain malignancies that alter the balance of the coagulation cascade.
• Inflammatory States: Elevated acute-phase reactants, such as fibrinogen, can influence the test’s clotting times and indicate systemic inflammation.
• Anticoagulant Therapy Contamination: It detects the residual presence of heparin or direct oral anticoagulants in the patient’s plasma, which alters the baseline APTT.
• Inadequate Sample Collection: It identifies pre-analytical errors, such as underfilled collection tubes, which alter the citrate-to-blood ratio and skew results.
• Factor V Wild-Type Status: It confirms normal, fully functional Factor V molecules that respond appropriately to APC-mediated downregulation.
• Combined Thrombophilic Defects: In complex cases, it helps identify patients who may have multiple co-existing clotting abnormalities.
• Risk of Recurrent VTE: It provides a quantitative basis for assessing the long-term risk of recurrent venous thromboembolism.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Laboratory & Diagnostic Centre, we understand that timely results are critical for clinical decision-making and patient peace of mind. The Activated Protein C Resistan test is processed using state-of-the-art, fully automated coagulation analyzers that ensure both speed and accuracy. Typically, the turnaround time for this specialized assay is within 24 to 48 hours from the time of sample collection. Once the analysis is complete, the results undergo a rigorous multi-level review by our consultant pathologists to ensure absolute clinical accuracy.

Patients can easily access their diagnostic reports through multiple convenient channels. Dr. Essa Lab offers a secure online reporting portal on our official website, where patients can view, download, and print their reports using the unique lab ID and password provided on their receipt. Additionally, reports can be accessed via our dedicated mobile application or received directly on WhatsApp. For patients who prefer physical copies, reports can be collected from any of our conveniently located collection centers across Karachi and other major cities.

Activated Protein C Resistan Findings Overview

The following table outlines the typical parameters evaluated during the Activated Protein C Resistan test, along with their clinical interpretation:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
APCR Clotting Ratio (APTT with APC / APTT without APC)	Ratio > 2.0 (indicates normal sensitivity to Activated Protein C)	Ratio < 2.0 (indicates resistance to Activated Protein C)
Modified APCR Ratio (using Factor V-deficient plasma)	Ratio > 2.0 (highly specific for genetic Factor V Leiden)	Ratio < 2.0 (confirms presence of Factor V Leiden mutation)
Baseline APTT (without APC)	Within normal reference range (typically 25-35 seconds)	Prolonged (due to lupus anticoagulant, heparin, or factor deficiency)
APTT with Added APC	Significant prolongation of clotting time (typically > 60 seconds)	Minimal prolongation of clotting time (clot forms rapidly despite APC)
Factor V Leiden Mutation Status	Negative (Wild-Type)	Positive (Heterozygous or Homozygous mutation)
Lupus Anticoagulant Screen	Negative (no interference with phospholipid-dependent clotting)	Positive (causes false-positive APCR results due to antibody interference)
Protein S Activity	Within normal reference range (typically 60-130%)	Decreased activity (contributes to functional APC resistance)
Factor VIII Activity	Within normal reference range (typically 50-150%)	Elevated activity (can cause mild, acquired APC resistance)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Activated Protein C Resistan?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified consultant pathologists, hematologists, and technologists specializing in coagulation disorders.
• Patient-Focused Care: We prioritize patient comfort, safety, and clear communication throughout the diagnostic process.
• Quality Diagnostic Services: Dr. Essa Lab is committed to maintaining the highest standards of quality control, participating in external quality assurance programs.
• Professional Reporting: We provide detailed, accurate, and easy-to-understand diagnostic reports that facilitate seamless clinical decision-making.
• Modern Diagnostic Approach: Utilizing state-of-the-art automated coagulation analyzers ensures highly reproducible and precise test results.
• Comfortable Environment: Our diagnostic centers across Karachi offer a clean, welcoming, and professional environment for all patients.
• Convenient Location: With a vast network of branches and collection points, patients can easily access our services near their homes.
• Commitment to Accurate Diagnosis: Established in 1987, Dr. Essa Lab has built decades of trust through an unwavering commitment to diagnostic excellence.